| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005686072 |
| P356 | DOI | 10.1007/S11845-013-0978-Y |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s11845-013-0978-y |
| P698 | PubMed publication ID | 23800980 |
| P5875 | ResearchGate publication ID | 242016954 |
| P2093 | author name string | O A Badary | |
| A Rizk | |||
| N A Sabry | |||
| N S Bazan | |||
| S Mokhtar | |||
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing | Q27008360 | ||
| A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose | Q28475004 | ||
| Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians | Q31016306 | ||
| High clearance of (S)-warfarin in a warfarin-resistant subject | Q34403760 | ||
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose | Q34417386 | ||
| A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. | Q34418092 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients | Q34571746 | ||
| Genetic determinants of response to warfarin during initial anticoagulation | Q34759038 | ||
| The impact of VKORC1-1639 G>A polymorphism on the maintenance dose of oral anticoagulants for thromboembolic prophylaxis in North India: A pilot study | Q35073505 | ||
| Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population | Q35803786 | ||
| Clinical consequences of cytochrome P450 2C9 polymorphisms | Q36002222 | ||
| VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. | Q53253348 | ||
| Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. | Q53257773 | ||
| Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. | Q53459208 | ||
| Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians | Q61850138 | ||
| A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial | Q73180786 | ||
| Genetic analysis of CYP2C9 polymorphism in a Japanese population | Q73834877 | ||
| Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients | Q80054365 | ||
| Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants | Q83364354 | ||
| Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies | Q84094664 | ||
| Frequency of cytochrome P450 2C9 mutant alleles in a Korean population | Q36055401 | ||
| Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives | Q36679917 | ||
| Role of pharmacogenomics in the management of traditional and novel oral anticoagulants | Q36848449 | ||
| Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues | Q36956360 | ||
| The largest prospective warfarin-treated cohort supports genetic forecasting | Q37071087 | ||
| Factors affecting the maintenance dose of warfarin | Q37110242 | ||
| Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin | Q37195550 | ||
| Pharmacogenetics of oral anticoagulants: a basis for dose individualization | Q37242614 | ||
| Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis | Q37639709 | ||
| Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen | Q38984342 | ||
| Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. | Q40506352 | ||
| Warfarin genotyping using three different platforms | Q42531773 | ||
| Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes | Q42540526 | ||
| Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients | Q42734047 | ||
| Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations | Q42791847 | ||
| Mayo clinic smoking status classification system: extensions and improvements. | Q42924796 | ||
| The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran | Q42967522 | ||
| Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population | Q43620426 | ||
| Interindividual variability in sensitivity to warfarin--Nature or nurture? | Q43705893 | ||
| Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population | Q43759147 | ||
| Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy | Q43942672 | ||
| Patient-specific factors predictive of warfarin dosage requirements | Q44146616 | ||
| Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients | Q44351201 | ||
| Genetic and environmental risk factors for oral anticoagulant overdose | Q44360560 | ||
| Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations | Q44486357 | ||
| Racial background is a determinant factor in the maintenance dosage of warfarin. | Q44534843 | ||
| Warfarin dose adjustments based on CYP2C9 genetic polymorphisms | Q44546032 | ||
| Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin | Q44787224 | ||
| Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study | Q44790546 | ||
| Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols | Q44879412 | ||
| Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype | Q45000639 | ||
| A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. | Q45052744 | ||
| Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients | Q46168730 | ||
| Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans | Q46174502 | ||
| Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. | Q46256641 | ||
| The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen | Q46537717 | ||
| VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. | Q46548969 | ||
| Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study | Q46619481 | ||
| CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients | Q46936372 | ||
| Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. | Q46943763 | ||
| Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population | Q46972802 | ||
| Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients | Q46979156 | ||
| Genetic analysis of the human cytochrome P450 CYP2C9 locus | Q48059311 | ||
| An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. | Q51871528 | ||
| Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. | Q51975669 | ||
| Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. | Q53248119 | ||
| P433 | issue | 2 | |
| P921 | main subject | (RS)-warfarin | Q407431 |
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 161-172 | |
| P577 | publication date | 2013-06-27 | |
| P1433 | published in | Irish Journal of Medical Science | Q6070885 |
| P1476 | title | Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism | |
| P478 | volume | 183 |
| Q42701943 | Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR. |
| Q36314728 | Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population. |
| Q39676335 | Frequency of Common CYP2C9 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population |
| Q39159490 | Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population. |
| Q38651234 | Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region. |
| Q36228428 | The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review |
| Q53695415 | The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians. |
Search more.